Boomi, a leader in intelligent integration and automation, has partnered with BASE Life Science, an Infosys company specializing in cloud-based solutions for the life sciences industry. This partnership expands on Boomi’s existing relationship with Infosys and strengthens integration capabilities for organizations transitioning from outdated technologies to the Veeva Vault Platform. This collaboration aligns with Boomi’s partnership with Veeva, a prominent provider of cloud software for the life sciences industry, known for its applications in enterprise content management, customer relationship management, and data management.
The collaboration between Boomi, BASE, and Veeva aims to support life sciences organizations in modernizing their operations for enhanced productivity throughout the drug development process. Developing a new prescription drug is a costly and complex endeavor. A Tufts Center for the Study of Drug Development report indicates an average cost of $2.6 billion to bring a new medicine to market. This figure encompasses clinical trial expenses and development time. Stringent regulatory requirements introduce further complexity, demanding meticulous navigation of approval processes to meet safety and efficacy standards. Integrating diverse data sources and managing input from various stakeholders complicate workflows, potentially leading to inefficiencies and delays in delivering innovative treatments to patients.
This partnership aims to simplify integration processes, allowing companies to prioritize their core mission of improving healthcare outcomes. Boomi will utilize BASE’s industry expertise to create tailored solutions that address the specific needs of pharmaceutical companies transitioning from legacy systems to the Veeva Vault Platform. This strategic collaboration underscores Boomi’s dedication to transforming the life sciences industry’s integration approach. By enabling organizations to overcome outdated technology limitations and embrace digital solutions, Boomi and BASE aim to drive value across all stages of drug development.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
